drugset / Trial / NCT07296029

CONFOCAL-2 Interventional Pilot Study

NCT07296029

Phase 1/2 Completed 16 enrolled Queen's University
NaSingle-groupOpen-labelTreatment

Summary

This study is designed to assess the feasibility of identifying and administering individualized blood pressure targets early critical illness. Recent literature suggests that individualized targets adapted to cerebral perfusion and autoregulation capacity may improve patient outcomes. In this study, cerebral autoregulation capacity is assessed by simultaneous trending of near-infared spectroscopy and arterial blood pressure for 24 hours, within patients' first 2 days in the ICU. The investigators will assess the feasibility of identifying patients' personal targets, then treating patients according to their personal targets for 48 hours. Clinical outcomes explored will include delirium.

Timeline

Start
2022-07-29
Primary completion
2025-02-08
Completion
2025-02-08

Drugs

EvaluationDrugModalityDoseRoute
Background Labetalol Small molecule
Background Norepinephrine Other / unclassified